Offer Fabian is a serial entrepreneur in the healthcare and high-tech industries. Prior to co-founding Musli, Offer served as Vice President of Commercial Development at InSightec, maker of MR-guided focused ultra-sound solutions. Offer was co-founder and co-CEO of Medial Research, developing and marketing big-data based cancer screening technologies. Before moving to the healthcare sector, Offer held various CEO and VP positions with telecommunications and eCommerce companies. Offer holds an MSc. In Computer Science from the Tel-Aviv University.
Dr. Osnat Ashur-Fabian (Osi) is a co-founder and co-inventor of the Musli cancer treatment. Osi is the Head of the Translational Hemato-Oncology Lab at Meir Medical Center in Kfar Saba, and holds an Associate Professor position at the Tel-Aviv University Sackler School of Medicine. Prior to that, Osi held post-doctorate and later senior researcher positions at the Cancer Research Institute in Sheba Medical Center. Osi is a serial inventor of novel oncological APIs in various phases of development. Osi holds Ph.D. and MSc. Degrees from the Sackler School of Medicine at the Tel-Aviv University.
Eran Perry is a venture capital specialist focused on the healthcare sector. Prior to joining Musli, Eran served as a Partner at Israel Healthcare Ventures (IHCV). Prior to IHCV, Eran was a consultant in McKinsey & Company, serving clients in the Pharmaceuticals, Telecommunications, and Public sectors. Prior to that, Eran was a member of the Global Marketing group at Novartis Oncology in New Jersey, USA. Eran holds an MBA from Columbia University with a major in Finance, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.
Monique Ben-Am is an expert in pre-clinical and clinical research specializing in phase 3 studies. For more than 30 years, Monique served in various positions in Novartis, in Switzerland and in the US, mainly in clinical research. Monique managed the Clinical Research Team for the development of Glivec/Gleevec at Novartis including their vast patient access programs. After moving to Israel in 2004, Monique served as Director of Global Clinical Operations and Global Innovative R&D for Teva Pharmaceuticals, and held the position of Vice President of Clinical Affairs at BioCancell Therapeutics, and at TopSpin Medical. Monique holds an MSc in Physiology and Pharmacology from the Tel Aviv University.
Dr. Yoram Sela joined Musli after being involved in corporate pharmaceutical research and development for the last 25 years. A serial entrepreneur, Yoram is co-founder of My Nutraceuticals, Belvit Pharma, Alvit LCS Pharma, GC Group, Pharma2B and Sela Pharma. Yoram served as Vice President for R&D at Nesher Solutions, and at LycoRed, and was the Co-Founder and Head of R&D at Karma Pharm. Prior to that, for more than 15 years Yoram served in R&D management positions in Teva Pharmaceuticals, where he created and managed the drug-delivery unit. Yoram holds a Ph.D. and MSc. from the Hebrew University of Jerusalem's Casali Institute of Applied Chemistry.
Dr. Susan Alpert is Musli's Head of Regulatory Affairs. Prior, Susan held positions as senior vice president and chief regulatory officer at Medtronic and a similar role at C.R. Bard . Before joining Bard, Susan held a number of positions with the US FDA in both the drug and device centers, including 6 years as Director of the FDA's Office of Device Evaluation. Susan, principal of SFA Regulatory, is a pediatric infectious disease physician, has an MD from the University of Miami and a Ph.D. in medical microbiology from New York University.
Dr. Ruth Perets is practicing oncologist at the Oncology Division, Director of the Women's Cancer Laboratory, member of the Rambam Clinical Research Institute and Founder and Head of the Oncology Division phase 1 clinical trials of the Rambam Healthcare Campus in Haifa, Israel. Ruth holds MD and PhD degrees from the Faculty of Medicine of the Hebrew University at Hadassah Hospital, Jerusalem. Ruth is a former post-doctoral fellow at the Dana Farber Cancer Institute and Harvard Medical School.
Alon Kaplun is a pharmaceutical executive with 20 years of global drug development experience. During his career Alon led the development of new drug products of various dosage forms in a variety of therapeutic areas and clinical stages. Among the projects that he headed are the pharmaceutical development of Temodar for Injection at Schering-Plough, and the early clinical stage development of several personalized medicine oncology products at Merck. Alon holds DSc, MSc and BSc (Cum Laude) degrees in Chemical Engineering from the Technion - Israel Institute of Technology.